Skip to main content

Table 1 Statistical power with 75 patients

From: ICON: a randomized phase IIb study evaluating immunogenic chemotherapy combined with ipilimumab and nivolumab in patients with metastatic hormone receptor positive breast cancer

Randomisation Surv1 Surv2 HR
1:1 0.05 0.208 0.52
2:3 0.05 0.198 0.54
1:2 0.05 0.198 0.54
  1. Surv1 is the survival probability in the control group at the end of the study. Surv2 is the survival probability in the experimental group. HR, hazard ratio, effect size of the experimental to the control group